Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 5.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,079,708 shares of the company’s stock after selling 59,838 shares during the quarter. American Century Companies Inc.’s holdings in Centessa Pharmaceuticals were worth $18,085,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares during the period. Walleye Capital LLC purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $187,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after acquiring an additional 5,316 shares during the last quarter. HighVista Strategies LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $737,000. Finally, State Street Corp acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at approximately $777,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider David M. Chao sold 7,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now directly owns 225,007 shares of the company’s stock, valued at $3,863,370.19. This trade represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares in the company, valued at approximately $1,808,271.85. This represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 260,168 shares of company stock valued at $4,309,568. 11.59% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $14.38 on Tuesday. The business’s fifty day moving average is $16.46 and its two-hundred day moving average is $16.43. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The firm has a market cap of $1.90 billion, a P/E ratio of -9.40 and a beta of 1.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Morgan Stanley reiterated an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a report on Monday. They set an “overweight” rating and a $38.00 price objective on the stock. Finally, TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.